The US Food and Drug Administration needs to take a more proactive approach to communicating to counter the tide of misinformation consumers are exposed to, a new report commissioned by the agency instructs. However, FDA Commissioner Robert Califf and other experts cautioned that some of this work may need to be led by outside parties to ensure public buy in.
Prebunk: FDA Needs To Get Ahead Of Misinformation, But It Likely Can’t Drive The Effort
New report offers a five-point plan for FDA to improve the public’s understanding of its role including pushing the agency to be more proactive in listening for, spotting, and addressing misconceptions before they escalate. But experts caution that this must be done carefully, or it could fuel more distrust.

More from Agency Leadership
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.
One CDRH employee said the cuts already are having a major effect on morale.
More from Pink Sheet
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.